To ensure that all essential modern
medicines are manufactured in Russia in accordance with the highest quality
standards and made accessible to patients.
Natalya Papazova, Director General, CDRI LLC
About the company
Contact information
Chemical Diversity Research Institute
CDRI LLC (Chemical Diversity Research Institute), a member of the ChemRar Group, is a full-cycle pharmaceutical company engaged in the development and manufacturing of innovative and generic medicinal products, including active pharmaceutical ingredients (APIs). All activities are conducted in compliance with both international and national regulatory requirements.
CDRI adheres to the Russian Pharmacopoeia, the standards of the Russian Federation, and the regulatory frameworks of the EAEU, EMA, FDA, and ICH.
With over three decades of experience and a state-of-the-art research infrastructure, CDRI offers a comprehensive range of services, from drug discovery and development to commercial manufacturing and regulatory registration of APIs and finished dosage forms (FDFs) such as tablets, capsules, and injectable solutions.
CDRI's facilities undergo routine inspections by domestic and international pharmaceutical companies and regulatory bodies.
The company is licensed by the Ministry of Industry and Trade of the Russian Federation and holds a Good Manufacturing Practice (GMP) certificate issued under the EAEU framework. All medicinal products manufactured by CDRI are duly registered with and approved by the Ministry of Health of the Russian Federation.
All medicines are registered by the Ministry of Health of the Russian Federation and are approved for use in Russia.
Pharmaceutical quality System
CDRI operates a robust and continuously evolving pharmaceutical quality management system to ensure full compliance with GMP standards and regulatory requirements.
- Licensed for the production of APIs and finished dosage forms
- Certified for GMP compliance under the EAEU framework
- Comprehensive quality assurance system focused on patient safety
- Certified under Decision No. 77 of the EAEU Council dated 03.11.2016